Pavel O. Bogomolov
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Pavel O. Bogomolov has a total of 300 co-authors. Here are the top co-authors by number of shared publications:
- Aleksey O. Bueverov
Moscow Regional Research and Clinical Institute (MONIKI)
13 shared publications - Ekaterina Evgenyevna Mishina
Endocrinology Research Centre
5 shared publications - Igor Veniaminovich Maev
Department of Internal Disease Propaedeutics and Gastroenterology, Russian University of Medicine, 127473 Moscow, Russia
5 shared publications - Natalia A. Barsukova
Moscow Regional Research and Clinical Institute named after M.F. Vladimirsky (MONIKI)
4 shared publications - Vladimir Petrovich Chulanov
Engelhardt Institute of Molecular Biology, Russian Academy of Science, Moscow 119991, Russia
4 shared publications - Aiman Silkanovna Sarsenbaeva
South Ural State Medical University
3 shared publications
Latest Publications
- 12 November 2026
- Published by Russian Gastroenterolgocial Society in Russian Journal of Gastroenterology, Hepatology, Coloproctology
- Vol. 36 (5)
Effectiveness of Empirical first-line H. pylori Eradication Therapy Among 15 cities in Russia: Results From 2013 to 2024 of the European Registry on Helicobacter pylori Management (Hp-EuReg)
Background. According to recent studies, the prevalence rate of Helicobacter pylori (H. pylori) infection in Russia mounts over 30 %. However, a comprehensive evaluation of the effectiveness of different eradication regimens in Russia has not yet been performed. Aim: To evaluate the first-line empirical therapy prescriptions and effectiveness in Russia between 2013 and 2024. Methods. Treatment-naïve cases were evaluated among 15 Russian cities between 2013–2024 using the data from the European Registry on H. pylori Management (Hp-EuReg) collected via an e-CRF hosted on AEGREDCap. Effectiveness was assessed by modified intention-to-treat (mITT) analysis. A quality review of data was performed against inconsistencies. All patients treated with an eradication regimen containing rebamipide were excluded from the current analysis. Results. Overall, 10,365 patients (average age 45 years; 64 % women), receiving first-line empirical eradication therapy were analysed. Quadruple therapy including a proton pump inhibitor (PPI), bismuth, amoxicillin and clarithromycin prescribed for 14 days achieved optimal (> 90 %) mITT effectiveness in Saint Petersburg, Perm, Chelyabinsk, and Khabarovsk. The effectiveness of 14-day triple therapy with PPI, amoxicillin and clarithromycin, prescribed to 31 % of patients, varied from 62 % in Novosibirsk to 97 % in Omsk, achieving a mean rate of 83 % across all the cities. The classical 14-day bismuth quadruple therapy (PPI-bismuth-metronidazole-tetracycline) was prescribed to 3.7 % of patients, providing optimal (> 90 %) effectiveness in Moscow and Saint Petersburg. The overall effectiveness was higher when high-dose PPI was prescribed (94 %), followed by standard(90 %) and low-dose (83 %). Similarly, the overall eradication rate was higher with 14-day prescriptions (91 %), followed by 10and 7-day (86 % and 73 %, respectively). Probiotics used as adjuvant in empirical eradication therapy increased effectiveness from 79 % to 92 % in standard triple (PPI-amoxicillin-clarithromycin) therapy, from 91 % to 95 % in quadruple PPI-bismuth-amoxicillin-clarithromycin therapy, and from 93 % to 96 % in quadruple PPI-bismuth-metronidazole-tetracycline regimen. Conclusion. In Russia, substantial regional variability was observed in the prescription of H. pylori first-line eradication regimens. Bismuth-containing quadruple therapies (either with metronidazole-tetracycline or amoxicillin-clarithromycin) achieved optimal (> 90 %) effectiveness, particularly when prescribed for 14 days and with high-dose PPI. Adjunctive probiotic use further improved eradication rates.
- 12 November 2026
- Published by Russian Gastroenterolgocial Society in Russian Journal of Gastroenterology, Hepatology, Coloproctology
- Vol. 36 (5)
Effectiveness of Empirical first-line H. pylori Eradication Therapy Among 15 cities in Russia: Results From 2013 to 2024 of the European Registry on Helicobacter pylori Management (Hp-EuReg)
Background. According to recent studies, the prevalence rate of Helicobacter pylori (H. pylori) infection in Russia mounts over 30 %. However, a comprehensive evaluation of the effectiveness of different eradication regimens in Russia has not yet been performed. Aim: To evaluate the first-line empirical therapy prescriptions and effectiveness in Russia between 2013 and 2024. Methods. Treatment-naïve cases were evaluated among 15 Russian cities between 2013–2024 using the data from the European Registry on H. pylori Management (Hp-EuReg) collected via an e-CRF hosted on AEGREDCap. Effectiveness was assessed by modified intention-to-treat (mITT) analysis. A quality review of data was performed against inconsistencies. All patients treated with an eradication regimen containing rebamipide were excluded from the current analysis. Results. Overall, 10,365 patients (average age 45 years; 64 % women), receiving first-line empirical eradication therapy were analysed. Quadruple therapy including a proton pump inhibitor (PPI), bismuth, amoxicillin and clarithromycin prescribed for 14 days achieved optimal (> 90 %) mITT effectiveness in Saint Petersburg, Perm, Chelyabinsk, and Khabarovsk. The effectiveness of 14-day triple therapy with PPI, amoxicillin and clarithromycin, prescribed to 31 % of patients, varied from 62 % in Novosibirsk to 97 % in Omsk, achieving a mean rate of 83 % across all the cities. The classical 14-day bismuth quadruple therapy (PPI-bismuth-metronidazole-tetracycline) was prescribed to 3.7 % of patients, providing optimal (> 90 %) effectiveness in Moscow and Saint Petersburg. The overall effectiveness was higher when high-dose PPI was prescribed (94 %), followed by standard(90 %) and low-dose (83 %). Similarly, the overall eradication rate was higher with 14-day prescriptions (91 %), followed by 10and 7-day (86 % and 73 %, respectively). Probiotics used as adjuvant in empirical eradication therapy increased effectiveness from 79 % to 92 % in standard triple (PPI-amoxicillin-clarithromycin) therapy, from 91 % to 95 % in quadruple PPI-bismuth-amoxicillin-clarithromycin therapy, and from 93 % to 96 % in quadruple PPI-bismuth-metronidazole-tetracycline regimen. Conclusion. In Russia, substantial regional variability was observed in the prescription of H. pylori first-line eradication regimens. Bismuth-containing quadruple therapies (either with metronidazole-tetracycline or amoxicillin-clarithromycin) achieved optimal (> 90 %) effectiveness, particularly when prescribed for 14 days and with high-dose PPI. Adjunctive probiotic use further improved eradication rates.
- Open Access
- 5 September 2026
- Published by Russian Gastroenterolgocial Society in Russian Journal of Gastroenterology, Hepatology, Coloproctology
- Vol. 36 (4) , 67-74
Efficacy and Safety of an 8-Week Antiviral Therapy for Chronic Hepatitis C with Ravidasvir and Sofosbuvir
Introduction. Hepatitis C virus (HCV) genotype 3 is associated with accelerated progression of liver disease; therefore, individuals infected with this genotype represent a clinically significant subgroup of patients. Despite the high efficacy of direct-acting antivirals, the optimal duration of therapy remains a subject of debate. Aim. To evaluate, in a real-world clinical setting, the efficacy and safety of an 8-week treatment regimen consisting of ravidasvir (200 mg) and sofosbuvir (400 mg) once daily in treatment-naive patients with chronic hepatitis C virus genotype 3 (HCV-3) infection and F0–F2 liver fibrosis (according to the METAVIR score). Materials and methods. This prospective, single-cohort, observational study (ClinicalTrials.gov, NCT07316842) enrolled 30 patients with HCV-3; the final per-protocol analysis included 29 patients who completed the full course of antiviral therapy and were available for the assessment of sustained virological response 12 weeks after treatment cessation (SVR12). The diagnosis of HCV-3 was verified in accordance with the Clinical Guidelines “Chronic Hepatitis C”, approved by the Scientific and Practical Council of the Ministry of Health of the Russian Federation. The mean age of the patients was 40.4 ± 7.1 years, and 65.5 % were men. The stage of liver fibrosis was determined by transient elastography using the FibroScan device (Echosens, France). The distribution of fibrosis stages was as follows: F0 — 44.8 %, F1 — 48.3 %, and F2 — 6.9 %. The primary endpoint was the achievement of SVR12, while the secondary endpoints included the achievement of aviremia 4 weeks after antiviral therapy completion (SVR4), viral load dynamics, changes in ALT and AST activity during treatment, as well as the safety and tolerability of the antiviral therapy. Results. In patients with HCV-3 and F0–F2 liver fibrosis (according to the METAVIR score), SVR12 was registered in 28 out of 29 patients (96.6 %; 95% CI: 82.8–99.4). SVR4 was achieved in 24 out of 25 patients with available data (96.0 %; 95% CI: 80.5–99.3). The median viral load decreased from 8.3 × 10 5 IU/mL at baseline to an undetectable level after 4 weeks of treatment and remained at this level at the time of SVR12 assessment. The median ALT activity decreased from 115.2 to 18.0 U/L, and AST activity decreased from 66.0 to 23.3 U/L ( p < 0.001 for both parameters). No serious adverse events or treatment discontinuations due to adverse events were registered. Conclusion. The shortened 8-week antiviral therapy regimen with a combination of ravidasvir (200 mg) and sofosbuvir (400 mg) once daily in patients with HCV-3 without advanced liver fibrosis demonstrates high efficacy and a favourable safety profile in this cohort.
- 5 September 2026
- Published by Russian Gastroenterolgocial Society in Russian Journal of Gastroenterology, Hepatology, Coloproctology
- Vol. 36 (4) , 67-74
Open AccessEfficacy and Safety of an 8-Week Antiviral Therapy for Chronic Hepatitis C with Ravidasvir and Sofosbuvir
Introduction. Hepatitis C virus (HCV) genotype 3 is associated with accelerated progression of liver disease; therefore, individuals infected with this genotype represent a clinically significant subgroup of patients. Despite the high efficacy of direct-acting antivirals, the optimal duration of therapy remains a subject of debate. Aim. To evaluate, in a real-world clinical setting, the efficacy and safety of an 8-week treatment regimen consisting of ravidasvir (200 mg) and sofosbuvir (400 mg) once daily in treatment-naive patients with chronic hepatitis C virus genotype 3 (HCV-3) infection and F0–F2 liver fibrosis (according to the METAVIR score). Materials and methods. This prospective, single-cohort, observational study (ClinicalTrials.gov, NCT07316842) enrolled 30 patients with HCV-3; the final per-protocol analysis included 29 patients who completed the full course of antiviral therapy and were available for the assessment of sustained virological response 12 weeks after treatment cessation (SVR12). The diagnosis of HCV-3 was verified in accordance with the Clinical Guidelines “Chronic Hepatitis C”, approved by the Scientific and Practical Council of the Ministry of Health of the Russian Federation. The mean age of the patients was 40.4 ± 7.1 years, and 65.5 % were men. The stage of liver fibrosis was determined by transient elastography using the FibroScan device (Echosens, France). The distribution of fibrosis stages was as follows: F0 — 44.8 %, F1 — 48.3 %, and F2 — 6.9 %. The primary endpoint was the achievement of SVR12, while the secondary endpoints included the achievement of aviremia 4 weeks after antiviral therapy completion (SVR4), viral load dynamics, changes in ALT and AST activity during treatment, as well as the safety and tolerability of the antiviral therapy. Results. In patients with HCV-3 and F0–F2 liver fibrosis (according to the METAVIR score), SVR12 was registered in 28 out of 29 patients (96.6 %; 95% CI: 82.8–99.4). SVR4 was achieved in 24 out of 25 patients with available data (96.0 %; 95% CI: 80.5–99.3). The median viral load decreased from 8.3 × 10 5 IU/mL at baseline to an undetectable level after 4 weeks of treatment and remained at this level at the time of SVR12 assessment. The median ALT activity decreased from 115.2 to 18.0 U/L, and AST activity decreased from 66.0 to 23.3 U/L ( p < 0.001 for both parameters). No serious adverse events or treatment discontinuations due to adverse events were registered. Conclusion. The shortened 8-week antiviral therapy regimen with a combination of ravidasvir (200 mg) and sofosbuvir (400 mg) once daily in patients with HCV-3 without advanced liver fibrosis demonstrates high efficacy and a favourable safety profile in this cohort.
- Open Access
- 23 May 2026
- Published by MDPI AG in Antibiotics
- Vol. 15 (6) , 531
Effectiveness and Safety of First-Line Empirical Eradication Therapy with Rebamipide: Results from the European Registry on Helicobacter pylori Management (Hp-EuReg)
Background/Objective: Eradication of Helicobacter pylori typically uses acid-suppressing agents plus antimicrobials, but treatment failure may reach 20–30%. Adjunctive rebamipide has been proposed as a strategy to improve treatment outcomes. This study aimed to assess the effectiveness and safety of first-line empirical therapy when rebamipide was added to eradication regimens. Methods: Treatment-naïve patient data were collected between January 2020 and August 2024 from the European Registry on Helicobacter pylori Management (Hp-EuReg), an international, prospective, multicentre, observational study. Rebamipide-containing regimens were analysed and compared with those without rebamipide. Effectiveness was assessed using a modified intention-to-treat approach. Results: Overall, 4581 patients (mean age 48 ± 15 years, 64% women) from 15 Russian cities were included. From those, 820 patients received eradication therapy with rebamipide and 3761 without rebamipide. Overall effectiveness was significantly higher with rebamipide (731/763, 96%) than without it (2785/3059, 91%) (p = 0.0002). Rebamipide-containing triple therapy consisting of a proton-pump inhibitor (PPI), clarithromycin and amoxicillin was associated with effectiveness above 90%, while rebamipide-containing quadruple therapy consisting of a PPI, clarithromycin, amoxicillin and bismuth yielded a 97% eradication rate, compared with 79% and 95%, respectively, without rebamipide (p < 0.001). Adverse events were significantly more frequent in patients receiving rebamipide-containing regimens (46% vs. 29%, p < 0.0001), though none were serious or caused discontinuation. Compliance was similar in both groups (99% vs. 98.5%; p > 0.05). Conclusions: In this observational registry cohort, first-line empirical triple therapy with amoxicillin–clarithromycin, and quadruple therapy with amoxicillin–clarithromycin–bismuth, both prescribed with rebamipide, were associated with higher eradication rates than regimens without rebamipide.
- 23 May 2026
- Published by MDPI AG in Antibiotics
- Vol. 15 (6) , 531
Open AccessEffectiveness and Safety of First-Line Empirical Eradication Therapy with Rebamipide: Results from the European Registry on Helicobacter pylori Management (Hp-EuReg)
Background/Objective: Eradication of Helicobacter pylori typically uses acid-suppressing agents plus antimicrobials, but treatment failure may reach 20–30%. Adjunctive rebamipide has been proposed as a strategy to improve treatment outcomes. This study aimed to assess the effectiveness and safety of first-line empirical therapy when rebamipide was added to eradication regimens. Methods: Treatment-naïve patient data were collected between January 2020 and August 2024 from the European Registry on Helicobacter pylori Management (Hp-EuReg), an international, prospective, multicentre, observational study. Rebamipide-containing regimens were analysed and compared with those without rebamipide. Effectiveness was assessed using a modified intention-to-treat approach. Results: Overall, 4581 patients (mean age 48 ± 15 years, 64% women) from 15 Russian cities were included. From those, 820 patients received eradication therapy with rebamipide and 3761 without rebamipide. Overall effectiveness was significantly higher with rebamipide (731/763, 96%) than without it (2785/3059, 91%) (p = 0.0002). Rebamipide-containing triple therapy consisting of a proton-pump inhibitor (PPI), clarithromycin and amoxicillin was associated with effectiveness above 90%, while rebamipide-containing quadruple therapy consisting of a PPI, clarithromycin, amoxicillin and bismuth yielded a 97% eradication rate, compared with 79% and 95%, respectively, without rebamipide (p < 0.001). Adverse events were significantly more frequent in patients receiving rebamipide-containing regimens (46% vs. 29%, p < 0.0001), though none were serious or caused discontinuation. Compliance was similar in both groups (99% vs. 98.5%; p > 0.05). Conclusions: In this observational registry cohort, first-line empirical triple therapy with amoxicillin–clarithromycin, and quadruple therapy with amoxicillin–clarithromycin–bismuth, both prescribed with rebamipide, were associated with higher eradication rates than regimens without rebamipide.
- Open Access
- 28 February 2026
- Published by Central Research Institute for Epidemiology in Problems of Virology
- Vol. 71 (1) , 32-41
Results of a blood serum examination of residents of Moscow and the Moscow region after the end of the West Nile fever outbreak in 2021
The aim of this study was to determine the level of humoral immunity to the West Nile virus (WNV) in the Moscow region population after the end of the outbreak in October 2021, as well as to confirm the specificity of antibodies to WNV by comparatively testing patient sera for antibodies to the antigenically related endemic tick-borne encephalitis orthoflavivirus (TBEV) using ELISA-IgM, ELISA-IgG, and 50% plaque reduction neutralization test. Materials and methods. We analyzed 1,594 sera from outpatients-residents of Moscow and the surrounding region–who underwent outpatient examination in the winter of 2021 at Infectious Diseases Clinical Hospital No. 1 in Moscow (IKB No. 1) and medical institutions of the Moscow Regional Research Institute named after M.F. Vladimirsky Regional Research Institute (MONIKI) conducted a study without any connection to WNV infection in the summer-autumn of 2021. Results. All samples were negative in ELISA-IgM test with WNV and TBEV antigens. In an ELISA-IgG test with the WNV antigen, antibodies were detected in 64 samples (4.0%). All samples were tested for IgG antibodies to TBEV in an ELISA and neutralizing antibodies to WNV and TBEV in a 50% plaque reduction neutralization test. Specific antibodies to WNV were detected in 44 samples (68.8%), to TBEV in eleven (17.2%), and group-specific antibodies in nine (14.0%). According to the total data from the test of 1,594 sera from residents of the Moscow region, specific antibodies to WNV were detected in 2.8% of cases, to TBEV in 0.7%, and group-specific antibodies in 0.6%. Ten of the 11 individuals with specific IgG antibodies to TBEV were undergoing outpatient examination at Moscow’s Infectious Diseases Clinical Hospital No. 1 for a history of tick-borne encephalitis or for post-vaccination immunity testing following vaccination against this infection. The detection rate of specific antibodies to WNV in similar studies conducted in the same region in 2013 was 0.2%, while in 2021 it was 2.8%. The difference between these rates is statistically significant (p 0.01). Conclusion. Based on these data, it can be concluded that sporadic undiagnosed cases of WNV infection occurred in Moscow and the surrounding region between 2013 and 2021.
- 28 February 2026
- Published by Central Research Institute for Epidemiology in Problems of Virology
- Vol. 71 (1) , 32-41
Open AccessResults of a blood serum examination of residents of Moscow and the Moscow region after the end of the West Nile fever outbreak in 2021
The aim of this study was to determine the level of humoral immunity to the West Nile virus (WNV) in the Moscow region population after the end of the outbreak in October 2021, as well as to confirm the specificity of antibodies to WNV by comparatively testing patient sera for antibodies to the antigenically related endemic tick-borne encephalitis orthoflavivirus (TBEV) using ELISA-IgM, ELISA-IgG, and 50% plaque reduction neutralization test. Materials and methods. We analyzed 1,594 sera from outpatients-residents of Moscow and the surrounding region–who underwent outpatient examination in the winter of 2021 at Infectious Diseases Clinical Hospital No. 1 in Moscow (IKB No. 1) and medical institutions of the Moscow Regional Research Institute named after M.F. Vladimirsky Regional Research Institute (MONIKI) conducted a study without any connection to WNV infection in the summer-autumn of 2021. Results. All samples were negative in ELISA-IgM test with WNV and TBEV antigens. In an ELISA-IgG test with the WNV antigen, antibodies were detected in 64 samples (4.0%). All samples were tested for IgG antibodies to TBEV in an ELISA and neutralizing antibodies to WNV and TBEV in a 50% plaque reduction neutralization test. Specific antibodies to WNV were detected in 44 samples (68.8%), to TBEV in eleven (17.2%), and group-specific antibodies in nine (14.0%). According to the total data from the test of 1,594 sera from residents of the Moscow region, specific antibodies to WNV were detected in 2.8% of cases, to TBEV in 0.7%, and group-specific antibodies in 0.6%. Ten of the 11 individuals with specific IgG antibodies to TBEV were undergoing outpatient examination at Moscow’s Infectious Diseases Clinical Hospital No. 1 for a history of tick-borne encephalitis or for post-vaccination immunity testing following vaccination against this infection. The detection rate of specific antibodies to WNV in similar studies conducted in the same region in 2013 was 0.2%, while in 2021 it was 2.8%. The difference between these rates is statistically significant (p 0.01). Conclusion. Based on these data, it can be concluded that sporadic undiagnosed cases of WNV infection occurred in Moscow and the surrounding region between 2013 and 2021.
- 26 June 2025
- Published by Novosibirsk State Technical University in Proceedings of the Russian higher school Academy of sciences
- No. 2
High frequency signal adder
The paper presents the results of the development and investigation of the frequency properties of a wide-band adder of high-power high-frequency signals. The adder is intended for the construction of multichannel RF and microwave amplifiers used in transmitting de-vices of radio engineering systems, telecommunications, communica-tion systems, digital terrestrial television broadcasting, electronic war-fare equipment, as an equivalent antenna, as well as in medical equipment. This paper presents a two-input adder based on three co-axial or microstrip transmission line segments with the same 50 ohm impedance. At the same time, all three segments have a length of less than a quarter of the wavelength, which significantly reduces the weight and size indicators. The use of coaxial or microstrip transmis-sion line segments with a wave resistance of 50 ohms to build the adder ensures the operation of the adder at an input power level of several kW and significantly simplifies the design. By introducing shortening capacitors into each segment of the transmission line, the effect of the parasitic capacitance of a powerful film-type ballast re-sistor is neutralized and high-quality matching in the frequency band of up to 15% is achieved. Based on the considered adder, high-power multi-input summing microwave systems can be implemented.
- 26 June 2025
- Published by Novosibirsk State Technical University in Proceedings of the Russian higher school Academy of sciences
- No. 2
High frequency signal adder
The paper presents the results of the development and investigation of the frequency properties of a wide-band adder of high-power high-frequency signals. The adder is intended for the construction of multichannel RF and microwave amplifiers used in transmitting de-vices of radio engineering systems, telecommunications, communica-tion systems, digital terrestrial television broadcasting, electronic war-fare equipment, as an equivalent antenna, as well as in medical equipment. This paper presents a two-input adder based on three co-axial or microstrip transmission line segments with the same 50 ohm impedance. At the same time, all three segments have a length of less than a quarter of the wavelength, which significantly reduces the weight and size indicators. The use of coaxial or microstrip transmis-sion line segments with a wave resistance of 50 ohms to build the adder ensures the operation of the adder at an input power level of several kW and significantly simplifies the design. By introducing shortening capacitors into each segment of the transmission line, the effect of the parasitic capacitance of a powerful film-type ballast re-sistor is neutralized and high-quality matching in the frequency band of up to 15% is achieved. Based on the considered adder, high-power multi-input summing microwave systems can be implemented.
- 8 June 2025
- Published by Medical Informational Agency Publishers in Clinical Medicine (Russian Journal)
- Vol. 103 (2) , 137-145
Mixed cryoglobulinemia associated with chronic HCV infection: problems of diagnosis and treatment
Mixed cryoglobulinemia is the most common extrahepatic manifestation of chronic HCV infection. Objective of the study. To investigate the frequency and diagnostic criteria of mixed cryoglobulinemia (MCG) associated with chronic HCV infection. Material and methods. The study included 83 patients with chronic HCV infection, aged 50.5 ± 12.6 years, of which 37 (44.6%) were men. The presence of cryoglobulins (CG) was examined, the cryocrit value was calculated, and rheumatoid factor (RF), complement component C4, and individual parameters of cellular immunity were determined. The frequency of MCG, its manifest forms, and immunological disorders were assessed, as well as the impact of antiviral therapy. Results. MCG was found in 61.4% of patients. Manifest forms of the disease were more frequently observed in the group of patients with a cryocrit of 1% or higher compared to those with a cryocrit of 0.5–0.99% (p < 0.017). In a multifactorial model, at a threshold cryocrit value of 0.5%, the detection of CG correlated with the duration of HCV infection (p = 0.001), and at a cryocrit value of 1%, it also correlated with a decrease in complement component C4 (p < 0.025). A sustained virological response (SVR) 12 weeks after the completion of therapy with direct-acting antiviral agents (DAAs) was achieved in 100% of patients. Despite the elimination of the virus, 29.4% of patients continued to have cryoglobulinemia. In 80% of patients with cryoglobulinemic vasculitis, immunological disorders persisted after the disappearance of CG. Conclusion. MCG develops in more than half of patients with chronic HCV infection and can be diagnosed with cryocrit values exceeding 0.5%. Early initiation of DAA therapy is a key factor in the prevention of MCG. The development of SVR does not exclude the persistence of MCG and immunological disorders in the early period after antiviral therapy, which necessitates mandatory long-term monitoring of these parameters.
- 8 June 2025
- Published by Medical Informational Agency Publishers in Clinical Medicine (Russian Journal)
- Vol. 103 (2) , 137-145
Mixed cryoglobulinemia associated with chronic HCV infection: problems of diagnosis and treatment
Mixed cryoglobulinemia is the most common extrahepatic manifestation of chronic HCV infection. Objective of the study. To investigate the frequency and diagnostic criteria of mixed cryoglobulinemia (MCG) associated with chronic HCV infection. Material and methods. The study included 83 patients with chronic HCV infection, aged 50.5 ± 12.6 years, of which 37 (44.6%) were men. The presence of cryoglobulins (CG) was examined, the cryocrit value was calculated, and rheumatoid factor (RF), complement component C4, and individual parameters of cellular immunity were determined. The frequency of MCG, its manifest forms, and immunological disorders were assessed, as well as the impact of antiviral therapy. Results. MCG was found in 61.4% of patients. Manifest forms of the disease were more frequently observed in the group of patients with a cryocrit of 1% or higher compared to those with a cryocrit of 0.5–0.99% (p < 0.017). In a multifactorial model, at a threshold cryocrit value of 0.5%, the detection of CG correlated with the duration of HCV infection (p = 0.001), and at a cryocrit value of 1%, it also correlated with a decrease in complement component C4 (p < 0.025). A sustained virological response (SVR) 12 weeks after the completion of therapy with direct-acting antiviral agents (DAAs) was achieved in 100% of patients. Despite the elimination of the virus, 29.4% of patients continued to have cryoglobulinemia. In 80% of patients with cryoglobulinemic vasculitis, immunological disorders persisted after the disappearance of CG. Conclusion. MCG develops in more than half of patients with chronic HCV infection and can be diagnosed with cryocrit values exceeding 0.5%. Early initiation of DAA therapy is a key factor in the prevention of MCG. The development of SVR does not exclude the persistence of MCG and immunological disorders in the early period after antiviral therapy, which necessitates mandatory long-term monitoring of these parameters.
- Open Access
- 9 March 2025
- Published by Russian Gastroenterolgocial Society in Russian Journal of Gastroenterology, Hepatology, Coloproctology
- Vol. 35 (1) , 94-152
Clinical Guidelines of the Russian Society for the Study of the Liver, Russian Gastroenterological Association, Russian Society for the Prevention of Non-Communicable Diseases, Russian Association of Endocrinologists, Russian Scientific Medical Society of Therapists, National Society of Preventive Cardiology, Russian Association of Gerontologists and Geriatricians on Non-Alcoholic Fatty Liver Disease
Aim. The clinical guidelines are intended to provide information support for making decisions by gastroenterologists, general practitioners and internists that will improve the quality of medical care for patients with non-alcoholic fatty liver disease, taking into account the latest clinical data and principles of evidence-based medicine. Key points. Clinical guidelines contain information about current views on etiology, risk factors and pathogenesis of nonalcoholic fatty liver disease, peculiarities of its clinical course. Also given recommendations provide information on current methods of laboratory and instrumental diagnostics, invasive and non-invasive tools for nonalcoholic fatty liver disease and its clinical phenotypes assessment, approaches to its treatment, considering the presence of comorbidities, features of dispensary monitoring and prophylaxis. The information is illustrated with algorithms of differential diagnosis and physician's actions. In addition, there is information for the patient and criteria for assessing the quality of medical care. Conclusion. Awareness of specialists in the issues of diagnosis, treatment and follow-up of patients with nonalcoholic fatty liver disease contributes to the timely diagnosis and initiation of treatment, which in the long term will significantly affect their prognosis and quality of life.
- 9 March 2025
- Published by Russian Gastroenterolgocial Society in Russian Journal of Gastroenterology, Hepatology, Coloproctology
- Vol. 35 (1) , 94-152
Open AccessClinical Guidelines of the Russian Society for the Study of the Liver, Russian Gastroenterological Association, Russian Society for the Prevention of Non-Communicable Diseases, Russian Association of Endocrinologists, Russian Scientific Medical Society of Therapists, National Society of Preventive Cardiology, Russian Association of Gerontologists and Geriatricians on Non-Alcoholic Fatty Liver Disease
Aim. The clinical guidelines are intended to provide information support for making decisions by gastroenterologists, general practitioners and internists that will improve the quality of medical care for patients with non-alcoholic fatty liver disease, taking into account the latest clinical data and principles of evidence-based medicine. Key points. Clinical guidelines contain information about current views on etiology, risk factors and pathogenesis of nonalcoholic fatty liver disease, peculiarities of its clinical course. Also given recommendations provide information on current methods of laboratory and instrumental diagnostics, invasive and non-invasive tools for nonalcoholic fatty liver disease and its clinical phenotypes assessment, approaches to its treatment, considering the presence of comorbidities, features of dispensary monitoring and prophylaxis. The information is illustrated with algorithms of differential diagnosis and physician's actions. In addition, there is information for the patient and criteria for assessing the quality of medical care. Conclusion. Awareness of specialists in the issues of diagnosis, treatment and follow-up of patients with nonalcoholic fatty liver disease contributes to the timely diagnosis and initiation of treatment, which in the long term will significantly affect their prognosis and quality of life.
- Open Access
- 24 January 2025
- Published by Wiley in Liver International
- Vol. 45 (2) , e70008
Phase 2 Randomised Study of Bulevirtide as Monotherapy or Combined With Peg‐IFNα‐2a as Treatment for Chronic Hepatitis Delta
Background and Aim: Bulevirtide (BLV) leads to beneficial virologic and biochemical responses when given alone to treat hepatitis delta virus (HDV) infection, which causes the most severe form of chronic viral hepatitis. We evaluated 48 weeks of BLV monotherapy, BLV + tenofovir disoproxil fumarate (TDF) and BLV + pegylated interferon alfa‐2a (Peg‐IFNα‐2a), with 24‐week follow‐up.Methods: Ninety patients were enrolled into six arms of 15 each (A–F); 60 patients were included in the main randomisation (arms A–D), and 30 patients (arms E–F) were randomised to the extension phase: (A) Peg‐IFNα‐2a 180 μg once weekly (QW); (B) BLV 2 mg once daily (QD) + Peg‐IFNα‐2a 180 μg QW; (C) BLV 5 mg QD + Peg‐IFNα‐2a 180 μg QW; (D) BLV 2 mg QD; (E) BLV 10 mg QD + Peg‐IFNα‐2a 180 μg QW and (F) BLV 10 mg (5 mg twice daily) + TDF QD. The primary endpoint was undetectable HDV RNA at week (W)72.Results: At W72, 53%, 27%, 7%, 7% and 33% of patients achieved undetectable HDV RNA in arms B, C, D, E and F, respectively, versus 0% in arm A. More arm B versus A patients had a > 1 log10 IU/mL decline in or loss of hepatitis B surface antigen (HBsAg) at W72 (p = 0.017), including four patients with loss of HBsAg. Bile acid elevations were dose‐dependent and reversible following the completion of BLV treatment.Conclusions: BLV combined with Peg‐IFNα‐2a was well tolerated and resulted in high rates of HDV RNA undetectability off‐treatment.Trial Registration: NCT02888106
- 24 January 2025
- Published by Wiley in Liver International
- Vol. 45 (2) , e70008
Open AccessPhase 2 Randomised Study of Bulevirtide as Monotherapy or Combined With Peg‐IFNα‐2a as Treatment for Chronic Hepatitis Delta
Background and Aim: Bulevirtide (BLV) leads to beneficial virologic and biochemical responses when given alone to treat hepatitis delta virus (HDV) infection, which causes the most severe form of chronic viral hepatitis. We evaluated 48 weeks of BLV monotherapy, BLV + tenofovir disoproxil fumarate (TDF) and BLV + pegylated interferon alfa‐2a (Peg‐IFNα‐2a), with 24‐week follow‐up.Methods: Ninety patients were enrolled into six arms of 15 each (A–F); 60 patients were included in the main randomisation (arms A–D), and 30 patients (arms E–F) were randomised to the extension phase: (A) Peg‐IFNα‐2a 180 μg once weekly (QW); (B) BLV 2 mg once daily (QD) + Peg‐IFNα‐2a 180 μg QW; (C) BLV 5 mg QD + Peg‐IFNα‐2a 180 μg QW; (D) BLV 2 mg QD; (E) BLV 10 mg QD + Peg‐IFNα‐2a 180 μg QW and (F) BLV 10 mg (5 mg twice daily) + TDF QD. The primary endpoint was undetectable HDV RNA at week (W)72.Results: At W72, 53%, 27%, 7%, 7% and 33% of patients achieved undetectable HDV RNA in arms B, C, D, E and F, respectively, versus 0% in arm A. More arm B versus A patients had a > 1 log10 IU/mL decline in or loss of hepatitis B surface antigen (HBsAg) at W72 (p = 0.017), including four patients with loss of HBsAg. Bile acid elevations were dose‐dependent and reversible following the completion of BLV treatment.Conclusions: BLV combined with Peg‐IFNα‐2a was well tolerated and resulted in high rates of HDV RNA undetectability off‐treatment.Trial Registration: NCT02888106
- 1 January 2025
- Published by Dynasty Publishing House in Infekcionnye bolezni
- Vol. 23 (4)
Efficacy and safety of bulevirtide in the treatment of chronic hepatitis D – results of a multicenter real-world clinical trial
Objective. To analyze the efficacy and safety of bulevirtide in chronic hepatitis D (CHD) in real-world clinical practice. Patients and methods. Data were analyzed from 237 patients with CHD, exclusively at the compensated cirrhosis stage (68%), including 19 patients with HIV coinfection, high viral load (median HDV RNA level 6.8 log10 copies/ml). They received bulevirtide monotherapy (55%), combination therapy with peginterferon alfa (24%), combination therapy (at least 24 weeks) with a switch to monotherapy (17%), and monotherapy (at least 24 weeks) with a switch to combination therapy (4%). Results. The analysis confirmed 1) the high rate of virological response (VR 88% at 120 weeks), including complete virological response (cVR 38%); 2) increased efficacy with treatment duration, including partial virological response (pVR) early in treatment; 3) higher efficacy of combination therapy compared to monotherapy at 48 weeks (94% VR, including 55% cVR); 4) normalization of ALT activity in the majority of patients (80% at 120 weeks); 5) safety and good tolerability of treatment (absence of serious adverse events, discontinuation of treatment due to adverse events); 6) low incidence of clinical outcomes associated with liver disease (6.3%, including decompensation – 3.8%); 7) high efficacy and safety of treatment in compensated cirrhosis and HIV coinfection. In patients with unknown baseline HDV RNA levels, quantitative testing on treatment revealed compliance with VR, including cVR, or pVR in 71% of cases. Conclusion. The results of the first post-marketing, multicenter observational study in Russia demonstrated high virological and biological efficacy, safety, and good tolerability of bulevirtide in the treatment of chronic hepatitis D, including compensated cirrhosis and HIV coinfection. These data support 1) the need for long-term treatment to enhance virological efficacy and 2) the choice of combination therapy as first-line treatment (in the absence of contraindications or intolerance to IFN). Further accumulation of real-world treatment experience is necessary to develop optimal antiviral therapy tactics aimed at improving outcomes and curing the disease. Key words: bulevirtide, HIV infection, combination therapy, monotherapy, pegylated interferon, chronic hepatitis D, liver cirrhosis
- 1 January 2025
- Published by Dynasty Publishing House in Infekcionnye bolezni
- Vol. 23 (4)
Efficacy and safety of bulevirtide in the treatment of chronic hepatitis D – results of a multicenter real-world clinical trial
Objective. To analyze the efficacy and safety of bulevirtide in chronic hepatitis D (CHD) in real-world clinical practice. Patients and methods. Data were analyzed from 237 patients with CHD, exclusively at the compensated cirrhosis stage (68%), including 19 patients with HIV coinfection, high viral load (median HDV RNA level 6.8 log10 copies/ml). They received bulevirtide monotherapy (55%), combination therapy with peginterferon alfa (24%), combination therapy (at least 24 weeks) with a switch to monotherapy (17%), and monotherapy (at least 24 weeks) with a switch to combination therapy (4%). Results. The analysis confirmed 1) the high rate of virological response (VR 88% at 120 weeks), including complete virological response (cVR 38%); 2) increased efficacy with treatment duration, including partial virological response (pVR) early in treatment; 3) higher efficacy of combination therapy compared to monotherapy at 48 weeks (94% VR, including 55% cVR); 4) normalization of ALT activity in the majority of patients (80% at 120 weeks); 5) safety and good tolerability of treatment (absence of serious adverse events, discontinuation of treatment due to adverse events); 6) low incidence of clinical outcomes associated with liver disease (6.3%, including decompensation – 3.8%); 7) high efficacy and safety of treatment in compensated cirrhosis and HIV coinfection. In patients with unknown baseline HDV RNA levels, quantitative testing on treatment revealed compliance with VR, including cVR, or pVR in 71% of cases. Conclusion. The results of the first post-marketing, multicenter observational study in Russia demonstrated high virological and biological efficacy, safety, and good tolerability of bulevirtide in the treatment of chronic hepatitis D, including compensated cirrhosis and HIV coinfection. These data support 1) the need for long-term treatment to enhance virological efficacy and 2) the choice of combination therapy as first-line treatment (in the absence of contraindications or intolerance to IFN). Further accumulation of real-world treatment experience is necessary to develop optimal antiviral therapy tactics aimed at improving outcomes and curing the disease. Key words: bulevirtide, HIV infection, combination therapy, monotherapy, pegylated interferon, chronic hepatitis D, liver cirrhosis
- 1 January 2025
- Published by Dynasty Publishing House in Infekcionnye bolezni
- Vol. 23 (4)
Ravidasvir – a pan-genotypic NS5A inhibitor for the treatment of chronic hepatitis C
Chronic hepatitis C (CHC) is a viral disease primarily affecting the liver, characterized by prolonged persistence of hepatitis C virus (HCV) and a high risk of developing liver cirrhosis and hepatocellular carcinoma. Modern direct-acting antiviral agents achieve a sustained virologic response in over 95% of patients, with good tolerability and safety. The aim of this study is to review the characteristics, efficacy, and safety of ravidasvir, a next-generation antiviral drug for the treatment of CHC. The literature search was conducted in PubMed/MEDLINE, Embase, and ClinicalTrials.gov up to August 11, 2025, using the keywords: ravidasvir, NS5A inhibitor, HCV, Hepatitis C, efficacy, safety. The review included phase I–III clinical trials investigating ravidasvir in CHC. Ravidasvir is a pan-genotypic inhibitor of the hepatitis C virus nonstructural protein 5A (NS5A), developed as an affordable alternative to other direct-acting antiviral agents. Ravidasvir has been studied as part of interferon-free oral regimens containing sofosbuvir or danoprevir boosted with ritonavir, with or without ribavirin. Clinical trial results have demonstrated high efficacy of ravidasvir-containing regimens against HCV genotypes 1, 3, and 4, regardless of HIV co-infection, prior interferon-based treatment experience, or compensated liver cirrhosis. Thus, ravidasvir demonstrates high efficacy against HCV and an optimal safety and tolerability profile, making it a reliable directacting antiviral agent for the treatment of CHC, including in hard-to-treat patient populations. Key words: hepatitis C virus, chronic hepatitis C, NS5A protein, treatment, ravidasvir
- 1 January 2025
- Published by Dynasty Publishing House in Infekcionnye bolezni
- Vol. 23 (4)
Ravidasvir – a pan-genotypic NS5A inhibitor for the treatment of chronic hepatitis C
Chronic hepatitis C (CHC) is a viral disease primarily affecting the liver, characterized by prolonged persistence of hepatitis C virus (HCV) and a high risk of developing liver cirrhosis and hepatocellular carcinoma. Modern direct-acting antiviral agents achieve a sustained virologic response in over 95% of patients, with good tolerability and safety. The aim of this study is to review the characteristics, efficacy, and safety of ravidasvir, a next-generation antiviral drug for the treatment of CHC. The literature search was conducted in PubMed/MEDLINE, Embase, and ClinicalTrials.gov up to August 11, 2025, using the keywords: ravidasvir, NS5A inhibitor, HCV, Hepatitis C, efficacy, safety. The review included phase I–III clinical trials investigating ravidasvir in CHC. Ravidasvir is a pan-genotypic inhibitor of the hepatitis C virus nonstructural protein 5A (NS5A), developed as an affordable alternative to other direct-acting antiviral agents. Ravidasvir has been studied as part of interferon-free oral regimens containing sofosbuvir or danoprevir boosted with ritonavir, with or without ribavirin. Clinical trial results have demonstrated high efficacy of ravidasvir-containing regimens against HCV genotypes 1, 3, and 4, regardless of HIV co-infection, prior interferon-based treatment experience, or compensated liver cirrhosis. Thus, ravidasvir demonstrates high efficacy against HCV and an optimal safety and tolerability profile, making it a reliable directacting antiviral agent for the treatment of CHC, including in hard-to-treat patient populations. Key words: hepatitis C virus, chronic hepatitis C, NS5A protein, treatment, ravidasvir